Intra-Cellular Therapies
ITCI
#1493
Rank
A$21.19 B
Marketcap
A$198.98
Share price
0.00%
Change (1 day)
85.47%
Change (1 year)

Revenue for Intra-Cellular Therapies (ITCI)

Revenue in 2024 (TTM): A$1.03 Billion

According to Intra-Cellular Therapies's latest financial reports the company's current revenue (TTM ) is A$1.02 Billion. an increase over the revenue in the year 2023 that were of A$0.67 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Intra-Cellular Therapies from 2014 to 2024

Annual revenue

Year Revenue Change
2024 A$1.09 B61.28%
2023 A$0.67 B85.3%
2022 A$0.36 B224.83%
2021 A$0.11 B284.64%
2020 A$29.3 M33746.09%
2019 A$0.08 M
2018 N/A
2017 N/A
2016 N/A-100%
2015 A$0.04 M-93.71%
2014 A$0.66 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
MediciNova
MNOV
A$0.38 M-99.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
A$17.57 M-98.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Xencor
XNCR
A$0.25 B-75.41%๐Ÿ‡บ๐Ÿ‡ธ USA